Breast cancer patients with basal-like (25–27%) and HER2-enriched cancer (11–20%) have higher propensities to metastasize to the brain, compared with those in luminal A (8–15%) and luminal B (11%) subtypes (Kennecke et al., 2010). This evidence concerns the gene ERBB2 and breast carcinoma.